Taken together, our accumulating data demonstrates that Her-2 positive gastric cancer patients could have benefit from the 5-FU sequential treatment with AT101, because of inhibition of tumor APE1 expression in the 5-FU based therapeutic strategy. Here, APEX1 is linked to neoplasm.